(0.49%) 5 071.25 points
(0.38%) 38 213 points
(0.59%) 17 541 points
(0.76%) $79.60
(1.55%) $1.962
(0.64%) $2 325.70
(0.21%) $26.81
(1.55%) $969.70
(-0.05%) $0.933
(-0.09%) $11.02
(-0.15%) $0.797
(-0.68%) $92.63
Live Chart Being Loaded With Signals
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally...
Stats | |
---|---|
本日の出来高 | 78 240.00 |
平均出来高 | 488 024 |
時価総額 | 415.19M |
EPS | HKD0 ( 2023-08-29 ) |
Last Dividend | HKD0.0500 ( 2015-05-19 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -13.50 |
ATR14 | HKD0.0100 (1.23%) |
Austar Lifesciences Ltd 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Austar Lifesciences Ltd 財務諸表
Annual | 2023 |
収益: | HKD1.76B |
総利益: | HKD336.05M (19.05 %) |
EPS: | HKD-0.0636 |
FY | 2023 |
収益: | HKD1.76B |
総利益: | HKD336.05M (19.05 %) |
EPS: | HKD-0.0636 |
FY | 2022 |
収益: | HKD2.23B |
総利益: | HKD462.67M (20.76 %) |
EPS: | HKD0.170 |
FY | 2021 |
収益: | HKD2.02B |
総利益: | HKD479.01M (23.77 %) |
EPS: | HKD0.540 |
Financial Reports:
No articles found.
Austar Lifesciences Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0500 | 2015-05-19 |
Last Dividend | HKD0.0500 | 2015-05-19 |
Next Dividend | HKD0 | N/A |
Payout Date | 2015-06-26 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.0500 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.95 | -- |
Div. Sustainability Score | 4.80 | |
Div.Growth Potential Score | 1.476 | |
Div. Directional Score | 3.14 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2378.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1359.HK | Ex Dividend Junior | 2023-06-26 | Annually | 0 | 0.00% | |
0405.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
6806.HK | Ex Dividend Knight | 2023-06-26 | Annually | 0 | 0.00% | |
1908.HK | Ex Dividend Junior | 2023-06-01 | Sporadic | 0 | 0.00% | |
0941.HK | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
0064.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
2888.HK | Ex Dividend Junior | 2023-08-10 | Annually | 0 | 0.00% | |
1508.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
0558.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.000801 | 1.500 | 9.98 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.000775 | 1.200 | 9.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00205 | 1.500 | -1.088 | -1.632 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.336 | 0.800 | 8.32 | 6.65 | [1 - 3] |
quickRatioTTM | 0.992 | 0.800 | 8.87 | 7.10 | [0.8 - 2.5] |
cashRatioTTM | 0.139 | 1.500 | -0.339 | -0.508 | [0.2 - 2] |
debtRatioTTM | 0.224 | -1.500 | 6.27 | -9.41 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.130 | 2.00 | -0.0433 | -0.0866 | [0 - 30] |
freeCashFlowPerShareTTM | -0.199 | 2.00 | -0.0995 | -0.199 | [0 - 20] |
debtEquityRatioTTM | 0.625 | -1.500 | 7.50 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.179 | 1.000 | -0.348 | -0.348 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0102 | 1.000 | -2.20 | -2.20 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.134 | 1.000 | -1.857 | -1.857 | [0.2 - 2] |
assetTurnoverTTM | 0.968 | 0.800 | 6.88 | 5.51 | [0.5 - 2] |
Total Score | 4.80 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 205.47 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00205 | 2.50 | -0.700 | -1.632 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.199 | 2.00 | -0.0663 | -0.199 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.130 | 2.00 | -0.0433 | -0.0866 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.734 | 1.500 | 8.44 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0310 | 1.000 | -3.28 | 0 | [0.1 - 0.5] |
Total Score | 1.476 |
Austar Lifesciences Ltd
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。